

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 9 February 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	750,000		222,297,903
9 February 2026	200,000	316.75	63,350,902
10 February 2026	200,000	314.24	62,848,248
11 February 2026	200,000	306.43	61,286,959
12 February 2026	200,000	308.68	61,736,898
13 February 2026	200,000	311.38	62,275,730
Accumulated under the programme	1,750,000		533,796,640

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 143,527 B shares in the period from 9 February 2026 to 13 February 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 19,139,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.4% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 1,750,000 B shares at an average share price of DKK 305.03 per B share equal to a transaction value of DKK 533,796,640.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](https://www.facebook.com/novonordisk), [Instagram](https://www.instagram.com/novonordisk/), [X](https://www.x.com/novonordisk), [LinkedIn](https://www.linkedin.com/company/novonordisk/) and [YouTube](https://www.youtube.com/novonordisk).

Contacts for further information

Media:

Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

Investors:

Michael Novod
+45 3075 6050
nvno@novonordisk.com

Max Ung
+45 3077 6414
mxun@novonordisk.com

Alex Bruce
+45 34 44 26 13
axeu@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Christoffer Sho Togo Tullin
+45 3079 1471
cftu@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fpitr@novonordisk.com